GlassScriptPhysician profile
Steven R Ballesteros
NPI 1609226133
$6,598.68
in general payments reported to CMS, 2019-2025
10 companies · $974 in 2025
The $974 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $5,280 · 2023: $162 · 2024: $183 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757 · Travel and Lodging: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $757.20 |
| Travel and Lodging | $561.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,022.36 | 2022-2025 | Da Vinci Surgical System |
| W. L. Gore & Associates, INC. | $176.13 | 2024-2025 | Gore Synecor Biomaterial |
| Davol INC. | $97.68 | 2025 | Arista |
| Smith+Nephew, INC. | $93.63 | 2022-2024 | Collagenase Santyl |
| Merck Sharp & Dohme LLC | $70.95 | 2024-2025 | Zerbaxa, Dificid |
| Becton, Dickinson and Company | $40.82 | 2023-2024 | Phasix Mesh |
| Tela Bio, INC. | $37.99 | 2024 | Ovitex 2s |
| Baxter Healthcare | $29.52 | 2025 | Perclot |
| Integra Lifesciences Corporation | $16.37 | 2023 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Kerecis Limited | $13.23 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ballesteros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.